SP Scientific and Praxair Expand Technology Agreement
News May 29, 2012
SP Scientific, and Praxair Inc., headquartered in Danbury, CT, have announced the expansion of their collaborative relationship to commercialize Praxair's ControLyo™ Nucleation on Demand Technology.
The original agreement, signed in October 2010, gave SP Scientific the exclusive, global rights to commercialize the technology on Development Lyophilizers <1.0 m.
The Praxair ControLyo™ Technology was implemented on SP Scientific's Lyostar 3 Freeze Dryer in December 2010.
The expansion of the agreement allows SP Scientific to also equip its clinical, pilot and production dryers (Benchmark series and Hull Production Dryers) with the ControLyo™ Technology.
Additionally, the agreement calls for the transfer of technology to allow SP Scientific to retrofit existing Pilot and Production units in the field, regardless of the original manufacturer.
"This is a major step in SP's strategy of technology leadership in lyophilization," states Chuck Grant, CEO for SP Scientific. "Given the ability to offer the technology from development through scale-up to production, SP Scientific is ideally positioned to be the supplier of choice for ControLyo™ Technology."
"Praxair is pleased to extend our existing agreement to cover the full range of lyophilizers offered to the industry by SP Scientific, " said Rich Jarrett, Global Director of Marketing and Business Development for Praxair.
Jarrett continued, "Praxair's ControLyo™ Technology has seen quick industry adoption with SP Scientific's Lyostar 3 FreezeDryer and we look forward to providing the industry with nucleation control at all production levels."
ControLyo™ Technology offers many benefits to the pharmaceutical industry including: vial-to-vial uniformity, reduced cycle times, reduced protein aggregation and better conformance to the Food and Drug Administration's Process Analytical Technology (PAT) initiative.
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE